NanoVibronix, Inc. is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company's primary products include PainShield®, UroShield® and WoundShield®, all of which are portable devices suitable for administration at home without assistance of medical professionals.
Company profile
Ticker
NAOV
Exchange
Website
CEO
Brian Murphy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Avanos Medical • Edwards Lifesciences • Invacare • MSA Safety • Align Technology • Surgalign ...
Former names
Nano Vibronix Inc, Nano Vibronix, Inc.
SEC CIK
NAOV stock data
Latest filings (excl ownership)
8-K
NanoVibronix Announces Reverse Stock Split
8 Feb 23
8-K
NanoVibronix Provides Update on Expanding Access to PainShield
18 Jan 23
8-K
Nanovibronix Announces Results of Annual Meeting of Stockholders Held Today
15 Dec 22
8-K
NanoVibronix Announces $2.4 Million Registered
1 Dec 22
424B5
Prospectus supplement for primary offering
30 Nov 22
8-K
NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus
29 Nov 22
8-K
NanoVibronix Announces Interim Results of Clinical Study for UroShield
16 Nov 22
DEFA14A
Additional proxy soliciting materials
15 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
DEFA14A
Additional proxy soliciting materials
31 Oct 22
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 1.97 mm | 1.97 mm | 1.97 mm | 1.97 mm | 1.97 mm | 1.97 mm |
| Cash burn (monthly) | 657.33 k | 552.25 k | 313.33 k | 490.00 k | 654.67 k | 547.25 k |
| Cash used (since last report) | 2.86 mm | 2.40 mm | 1.36 mm | 2.13 mm | 2.85 mm | 2.38 mm |
| Cash remaining | -887.33 k | -430.23 k | 609.03 k | -159.45 k | -875.73 k | -408.48 k |
| Runway (months of cash) | -1.3 | -0.8 | 1.9 | -0.3 | -1.3 | -0.7 |
Institutional ownership, Q2 2022
16.2% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 16 |
| Opened positions | 0 |
| Closed positions | 6 |
| Increased positions | 2 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 3.27 mm |
| Total shares | 4.54 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Packer Paul | 1.67 mm | $1.28 mm |
| Hirschman Orin | 771.46 k | $589.00 k |
| Vanguard | 651.26 k | $410.00 k |
| Alpha Capital Anstalt | 645.72 k | $493.00 k |
| AFSIP Amtrust Financial Services | 248.15 k | $156.00 k |
| Geode Capital Management | 207.10 k | $127.00 k |
| Renaissance Technologies | 125.89 k | $79.00 k |
| STT State Street | 125.39 k | $77.00 k |
| NTRS Northern Trust | 46.87 k | $30.00 k |
| Cambridge Investment Research Advisors | 12.40 k | $8.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 Jan 23 | Thomas Mika | Common Stock | Buy | Acquire P | No | No | 0.25 | 50,000 | 12.50 k | 50,000 |
| 15 Jun 22 | Christopher M Fashek | Common Stock | Buy | Acquire P | No | No | 0.5957 | 40,000 | 23.83 k | 75,000 |
| 14 Jun 22 | Stephen Russell Brown | Common Stock | Buy | Acquire P | No | No | 0.5739 | 4,000 | 2.30 k | 4,000 |
| 1 Jun 22 | Aurora Cassirer | Common Stock | Buy | Acquire P | No | No | 0.69 | 2,000 | 1.38 k | 2,000 |
News
NanoVibronix Announces 1-For20 Reverse Stock Split
8 Feb 23
12 Health Care Stocks Moving In Friday's After-Market Session
27 Jan 23
12 Health Care Stocks Moving In Wednesday's After-Market Session
18 Jan 23
NanoVibronix Provides Update On Expanding Access To PainShield; Receives Interim Results Of Lifecycle Testing; Enactment Of Federal 'NOPAIN Act' Could Be A Catalyst
18 Jan 23
$12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying
6 Jan 23
Press releases
NanoVibronix Announces Reverse Stock Split
8 Feb 23
NanoVibronix Provides Update on Expanding Access to PainShield
18 Jan 23
NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today
15 Dec 22
NanoVibronix Announces Closing of $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
1 Dec 22
NanoVibronix Announces $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
29 Nov 22